# Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring a 90% Upside Potential in Biotech

- Link: https://www.directorstalkinterviews.com/trevi-therapeutics-inc-trvi-stock-analysis-exploring-a-90-upside-potential-in-biotech/4121234182
- Published: 2026-01-09T11:21:23+00:00
- Author: Madison Wilson

Trevi Therapeutics, Inc. (NASDAQ: TRVI) stands out in the biotech sector with a 
compelling story for investors seeking high potential returns. The company, headquartered
in New Haven, Connecticut, is at the forefront of developing treatments for chronic
cough and pruritus through its investigational therapy, Haduvio. As a clinical-stage
biopharmaceutical entity, Trevi is making strides in addressing unmet medical needs,
which has captured the attention of the investor community.

Despite a modest market cap of $1.44 billion, Trevi Therapeutics presents a significant
upside potential of 90.01%, based on analyst ratings. The current price of $11.21
per share is seen as substantially undervalued compared to the average target price
of $21.30, with analysts unanimously issuing ‘Buy’ ratings. Such optimism is fueled
by the company’s promising pipeline and strategic license agreement with Endo Pharmaceuticals,
enhancing its developmental and commercial capabilities.

Trevi’s flagship product, Haduvio, is an oral extended-release formulation of nalbuphine.
It is currently in various stages of clinical trials targeting chronic cough in 
idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, as well
as prurigo nodularis. The potential success of these trials could significantly 
alter the landscape for patients suffering from these conditions and, consequently,
the company’s financial trajectory.

From a valuation perspective, Trevi Therapeutics presents a complex picture. The
absence of a P/E ratio and negative EPS of -0.37 reflect its current unprofitability,
a common trait among clinical-stage biotechs still in the developmental phase. The
forward P/E ratio of -23.85 further underscores the near-term financial challenges
as the company invests heavily in research and development. However, the biotech
space often rewards future potential over immediate profitability, particularly 
when robust clinical results and regulatory milestones are on the horizon.

Technical indicators provide additional insights into Trevi’s current stock dynamics.
The stock is trading below its 50-day moving average of $12.07, yet significantly
above its 200-day moving average of $8.47, indicating a long-term upward trend. 
The RSI of 54.38 suggests a balanced momentum, neither overbought nor oversold, 
while the MACD and Signal Line readings imply a cautious stance in the short term.

Trevi Therapeutics does not currently offer a dividend, aligning with its strategic
focus on reinvesting capital into its pipeline rather than distributing profits.
This approach is typical for a company at this stage, emphasizing growth over income
generation.

For investors, the allure of Trevi Therapeutics lies in its innovative approach 
to tackling chronic conditions and the substantial market potential of its drug 
candidates. The unanimous buy ratings from analysts, coupled with the significant
price target range of $16.00 to $27.00, provide a strong case for those willing 
to embrace the risks inherent in biotech investments. As the company progresses 
through its clinical trials, positive outcomes could serve as catalysts for substantial
stock appreciation, making Trevi Therapeutics a compelling consideration for growth-
focused investors.

Share on: